Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) announced a share buyback of 50,000 shares on October 15, 2025, for a total transaction amount of approximately HKD 1.6948 million, with an average price of about HKD 33.90 per share [1] Group 1 - The current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The board believes that the share buyback demonstrates management's strong confidence in the long-term value of the enterprise [1] - The buyback is expected to enhance the group's market value and shareholder return capabilities [1] Group 2 - The share buyback aligns with the overall interests of the company and its shareholders [1]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) shares rose over 3%, currently trading at HKD 13.46 with a transaction volume of HKD 31.44 million, following the announcement of a share buyback plan [1] Group 1: Share Buyback Announcement - The company announced a share buyback authorization, with a maximum repurchase amount of HKD 20 million, subject to shareholder approval at the annual general meeting on June 12, 2025 [1] - The board believes that the current trading price does not accurately reflect the company's intrinsic value and that the buyback will demonstrate confidence in the company's business outlook and prospects [1] - The board is confident that the company's current financial resources are sufficient to support the proposed buyback while maintaining a robust financial position [1]

Core Viewpoint - Corning Pharmaceutical-B (09966) has seen a stock price increase of over 3%, currently trading at 13.46 HKD with a transaction volume of 31.44 million HKD, following the announcement of a share buyback program [1] Group 1: Share Buyback Announcement - The board of directors has resolved to repurchase ordinary shares from the open market, with a maximum amount of 20 million HKD, subject to shareholder approval at the annual general meeting on June 12, 2025 [1] - The board believes that the current trading price does not accurately reflect the company's intrinsic value and that the buyback will demonstrate confidence in the company's business outlook and ultimately benefit shareholders [1] - The board is confident that the company's current financial resources are sufficient to support the proposed share buyback while maintaining a robust financial position [1]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced a share buyback program, indicating that the current market price does not reflect the company's intrinsic value and expressing confidence in its business outlook and future prospects [1] Summary by Relevant Sections - **Share Buyback Authorization** - The board of directors resolved to repurchase ordinary shares from the open market, with a maximum amount of HKD 20 million [1] - This buyback is subject to approval at the shareholders' annual general meeting scheduled for June 12, 2025 [1] - **Rationale for Buyback** - The board believes that the current trading price of the shares does not accurately reflect the company's intrinsic value [1] - The buyback is seen as a demonstration of the company's confidence in its business outlook and future prospects [1] - The company aims to benefit from this buyback and create value for its shareholders [1] - **Financial Position** - The board is confident that the company's current financial resources are sufficient to support the proposed share buyback while maintaining a robust financial position [1]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced a share buyback program with a maximum amount of HKD 20 million, reflecting the board's confidence in the company's business outlook and intrinsic value [1] Summary by Relevant Sections Share Buyback Authorization - The board resolved to repurchase shares from the open market, subject to approval at the shareholders' annual meeting on June 12, 2025 [1] - The maximum amount for the share buyback is set at HKD 20 million [1] Rationale for Buyback - The board believes that the current trading price does not accurately reflect the company's intrinsic value [1] - The share buyback is seen as a demonstration of the company's confidence in its business prospects and aims to create value for shareholders [1] Financial Position - The board is confident that the company's current financial resources are sufficient to support the proposed share buyback while maintaining a robust financial position [1]

Core Viewpoint - The company, Innovent Biologics (02121.HK), announced the repurchase of 590,700 shares in the open market for a total consideration of HKD 4.81 million, reflecting confidence in its business outlook and future prospects [1] Summary by Relevant Sections - **Share Repurchase Details** - The company repurchased a total of 590,700 shares at a cost of HKD 4.81 million [1] - **Regulatory Compliance** - The share repurchase will comply with the company's articles of association, the Hong Kong Stock Exchange listing rules, and applicable laws and regulations [1] - **Management's Perspective** - The board believes that the share repurchase demonstrates confidence in the company's business outlook and will ultimately benefit the company and create value for shareholders [1] - **Financial Position** - The board asserts that the company's existing financial resources are sufficient to support the share repurchase while maintaining a robust financial position [1]

公司现时的财务状况稳健。董事会认为股份现时的成交价未能反映其内在价值。董事会相信，建议股份 购回可提升股份的价值，从而提高公司股东的回报。此外，董事会相信，建议股份购回反映公司对自身 的长远业务前景及公司的增长潜力充满信心，且最终将可惠及公司，并符合公司及公司股东整体的最佳 利益。 歌礼制药-B(01672)发布公告，其拟根据公司股东于2025年5月22日举行的公司股东周年大会上授予董事 会购回公司股份的一般授权行使其权力，在合适时间于公开市场上购回股份。根据购回授权，公司获准 购回最多9628.46万股股份，相当于股东周年大会日期已发行股份(不包括库存股份)总数的10%。 于2025年9月29日，董事会已决定行使购回授权，并根据市况不时于公开市场购回股份，以使用最多3亿 港元的资金(拨付自公司内部财务资源)进行建议股份购回。 ...

智通财经APP讯，歌礼制药-B(01672)发布公告，其拟根据公司股东于2025年5月22日举行的公司股东周 年大会上授予董事会购回公司股份的一般授权行使其权力，在合适时间于公开市场上购回股份。根据购 回授权，公司获准购回最多9628.46万股股份，相当于股东周年大会日期已发行股份(不包括库存股份)总 数的10%。 公司现时的财务状况稳健。董事会认为股份现时的成交价未能反映其内在价值。董事会相信，建议股份 购回可提升股份的价值，从而提高公司股东的回报。此外，董事会相信，建议股份购回反映公司对自身 的长远业务前景及公司的增长潜力充满信心，且最终将可惠及公司，并符合公司及公司股东整体的最佳 利益。 于2025年9月29日，董事会已决定行使购回授权，并根据市况不时于公开市场购回股份，以使用最多3亿 港元的资金(拨付自公司内部财务资源)进行建议股份购回。 ...

公司现时的财务状况稳健。董事会认为股份现时的成交价未能反映其内在价值。董事会相信，建议股份 购回可提升股份的价值，从而提高公司股东的回报。建议股份购回将以公司除公司2018年全球发售所得 款项净额及于2025年8月25日完成的根据一般授权配售现有股份及补足认购新股份所得款项净额外的内 部财务资源拨付。 格隆汇10月2日丨歌礼制药-B(01672.HK)发布公告，2025年9月29日，董事会已决定行使购回授权，并根 据市况不时于公开市场购回股份，以使用最多3亿港元的资金（拨付自公司内部财务资源）进行建议股 份购回。 ...

本报讯 （记者梁傲男）9月29日，找钢产业互联集团（以下简称"找钢集团"）发布公告称，董事会决议 行使购回授权，拟在公开市场以现有内部财务资源以最高价每股A类股份10港元购回不超过约1.07亿股 A类股份。 董事会认为，A类股份现有交易价格未能反映公司内在价值及业务前景，股份购回体现公司对其长期业 务前景的信心，符合公司及股东的最佳利益。 （编辑 郭之宸） ...